about
Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patientsSurveillance of bloodstream infections in pediatric cancer centers - what have we learned and how do we move on?Effects of high-yield thrombocytapheresis on the quality of platelet products.Exploring the association of hemoglobin level and adverse events in children with cancer presenting with fever in neutropeniaA prospective multicenter study of microbiologically defined infections in pediatric cancer patients with fever and neutropenia: Swiss Pediatric Oncology Group 2003 fever and neutropenia study.Butyrate increases intracellular calcium levels and enhances growth hormone release from rat anterior pituitary cells via the G-protein-coupled receptors GPR41 and 43The influence of different fever definitions on the rate of fever in neutropenia diagnosed in children with cancerProgression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis.Normal values for pancreatic stone protein in different age groups.Clustering of health behaviours in adult survivors of childhood cancer and the general populationCause-specific long-term mortality in survivors of childhood cancer in Switzerland: A population-based study.Real-time quantitative broad-range PCR assay for detection of the 16S rRNA gene followed by sequencing for species identificationManagement of fever and neutropenia in paediatric cancer patients: room for improvement?Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update.Spatial clustering of childhood leukaemia in Switzerland: A nationwide study.Childhood cancer and residential exposure to highways: a nationwide cohort study.Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer.M-ficolin concentrations in cord blood are related to circulating phagocytes and to early-onset sepsis.Predicting bacteremia in children with cancer and fever in chemotherapy-induced neutropenia: results of the prospective multicenter SPOG 2003 FN study.M-ficolin in the neonatal period: Associations with need for mechanical ventilation and mortality in premature infants with necrotising enterocolitis.Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study.Core outcomes and definitions for pediatric fever and neutropenia research: a consensus statement from an international panel.The reporting of outcomes in studies of fever and neutropenia in children with cancer: time for consensus.Serum Concentrations of Mannan-Binding Lectin (MBL) and MBL-Associated Serine Protease-2 and the Risk of Adverse Events in Pediatric Patients With Cancer and Fever in Neutropenia.Bacteria causing bacteremia in pediatric cancer patients presenting with febrile neutropenia--species distribution and susceptibility patterns.Different fever definitions and the rate of fever and neutropenia diagnosed in children with cancer: a retrospective two-center cohort study.Population mixing and the risk of childhood leukaemia in Switzerland: a census-based cohort study.First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.Serious medical complications in children with cancer and fever in chemotherapy-induced neutropenia: results of the prospective multicenter SPOG 2003 FN study.M-ficolin in children with cancer.H-ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients.Risk prediction of fever in neutropenia in children with cancer: a step towards individually tailored supportive therapy?Deficiency of mannose-binding lectin-associated serine protease-2 associated with increased risk of fever and neutropenia in pediatric cancer patients.Real-time broad-range PCR versus blood culture. A prospective pilot study in pediatric cancer patients with fever and neutropenia.Serum levels of mannose-binding lectin and the risk of fever in neutropenia pediatric cancer patients.Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia.[Diagnostic procedures and management of Fever in pediatric cancer patients]Low risk episodes of fever and neutropenia in pediatric oncology: Is outpatient oral antibiotic therapy the new gold standard of care?Fever in neutropenia in children and adolescents: evolution over time of main characteristics in a single center, 1993-2001.Serum C-reactive protein in children with adenovirus infection.
P50
Q21261533-7628B506-A093-437B-AAF3-D11981B693B4Q26747635-9AC3386D-9E4E-45DB-909A-AE5A80374F2BQ33377710-CF5AB6D7-6B38-48C9-879D-8381B6886C54Q33895962-681BC092-08BC-4780-9795-76A3A43A24E2Q34065997-C853E26F-7B68-4481-A19E-31A68213580BQ34331559-2C8DF1FC-F809-4AC6-BAB4-17132FAEDD73Q35074650-13D3FFB1-B449-4799-962A-0ABB467C9935Q35221266-D13229CE-72B0-4D47-85A7-CCB9AC1C46C8Q35847403-85A14D08-49FF-4727-896E-7E3F3EE56742Q36089965-92E154D9-4134-4D14-BBC8-F6C4C65D49FEQ37352288-4472D82D-6110-42A9-995C-82F75CDD867DQ38471919-2F9C7168-1BF5-43C7-9AC6-D38F8889A651Q38588691-DE1F3619-20EF-491C-B471-6D35F6FEA565Q38689071-B9D5B05D-9EC9-4565-BD0A-BE62D0231620Q38728214-36850D66-1DD1-48AF-B079-437AF6E27D70Q39483846-BB1321FD-76EC-441A-93CC-24F87F15C2BBQ39621071-CD1CC5B9-7421-493D-8837-30446F7EAA77Q39644662-95BD3424-B910-4CA0-A118-1747C6BF9DDFQ39773225-A7DE9695-22F5-4FA1-9EEB-66D3617A2712Q39835929-F026C219-4782-4E9A-93AF-796A7C5A99C9Q39891473-4382517C-F9AD-468B-AE4E-FC2EFF8A0BB3Q40180396-5FD74F49-F89E-4715-9432-541E3F1E7CDCQ40242721-8E926829-4939-4755-AC48-39D4314D21E2Q40245989-79588C8E-F51C-4C09-B147-9FE95E4DA2D5Q40251397-E89B6FA6-518B-4EAF-96CC-7DC0CA9DAD9AQ40266414-16DAF1DF-D059-494A-AE50-D88861BF1695Q40283089-150BBB4C-88A6-43F0-9443-A9D903487C65Q40298464-B72133AF-BC48-4C48-95B1-1EACEE789DE1Q40315460-9DBE238B-E9F1-45CC-9CC1-3F915EFA2D23Q40342355-411A0AF8-D1AB-4487-A6E9-3A12E7EB9924Q40382932-A426B2E2-43E3-4BCF-9FBF-852049E803F1Q40411235-3F5B5C49-6FEC-4B2A-AA4C-A9DB5C0278C7Q40435140-92B1CB11-C7D1-4026-B437-8719ACC34ED9Q40456529-44722B35-D6A6-4D1B-A386-8F40E492D6ABQ40463161-D244926A-3A7A-4127-812D-FDE9F0109DF6Q40467192-6C8E60CA-DE94-4D4E-A670-9DDF2ECF6CAAQ40493919-CEC5AABD-CCDC-40CE-AC44-C8ADE2DB743CQ40513704-CE737F6A-A0BE-438E-B6B7-331E2DC58A91Q40530230-F5ECAF42-2AE7-45E8-8197-09295A1E9B59Q40571269-3D5F7328-E9D3-4A00-9F91-CC292CBAB913
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roland A Ammann
@ast
Roland A Ammann
@en
Roland A Ammann
@es
Roland A Ammann
@nl
Roland A Ammann
@sl
type
label
Roland A Ammann
@ast
Roland A Ammann
@en
Roland A Ammann
@es
Roland A Ammann
@nl
Roland A Ammann
@sl
prefLabel
Roland A Ammann
@ast
Roland A Ammann
@en
Roland A Ammann
@es
Roland A Ammann
@nl
Roland A Ammann
@sl
P106
P21
P31
P496
0000-0002-1902-2352